ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0829

Adult Onset Still’s Disease: A Retrospective Study of Objective Manifestations and Outcomes

Caroline Bui1, Tim Collins2, Kumar Venkat3, Napatkamon Ayutyanont2, Kim Vickery4 and Scott Kubomoto2, 1Riverside Community Hospital/University of California Riverside, Riverside, CA, 2Riverside Community Hospital/University of California Riverside, Riverside, 3University of California Riverside/Riverside Community Hospital, Riverside, 4HCA Healthcare, Riverside

Meeting: ACR Convergence 2022

Keywords: Still's disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Adult Onset Still’s Disease (AOSD) is a complex and rare inflammatory disease with life threatening complications. Due to its rarity and wide ranging clinical presentation, there is a lack of data regarding this patient population and their outcomes.

Methods: We retrospectively identified hospitalized patients within the 185 hospital HCA database between 2016-2021 who were aged 18+ with a diagnosis of AOSD via ICD 10 code M06.1. Further data was collected regarding patient demographics, objective lab findings, and outcomes.

Results: We identified 185 patients with AOSD with an incidence rate of 0.16 to 0.21 per 100,000. Mean age was 47 and nearly 70% were female. Objective presentations included elevated inflammatory markers (ESR 55.11 +/- 36.52, CRP 12.26 +/- 27.48, and ferritin 7141.23 +/- 11536.60), leukocytosis (12.15 (+/- 5.86)), and unspecified anemia (23%). Nearly 24% of patients required ICU level of care and overall mortality rate was 3.2%. Data regarding concurrent diagnoses of pneumonia were also included. 11.9% had a coexisting pneumonia which was associated with an increase in ICU admission (likelihood ratio 7.4, p = 0.007) but not an increase in mortality.

Conclusion: Our study establishes patient demographics and common objective findings to better understand and diagnose this rare disease. Incidence rates increased over time, suggesting increased awareness and improved diagnosis. Our data was consistent with prior studies suggesting that AOSD more commonly affects caucasian females. Objective data also further solidified known lab abnormalities in this group including elevated inflammatory markers, leukocytosis, and anemia. Prior studies have suggested that concomitant pneumonia caused greater severity of disease with increased mortality. This differed in our population, although our study was limited by lack of follow-up data. Further studies may analyze patients who fit Yamaguchi criteria as well as complications and long term outcomes.


Disclosures: C. Bui, None; T. Collins, None; K. Venkat, None; N. Ayutyanont, None; K. Vickery, None; S. Kubomoto, None.

To cite this abstract in AMA style:

Bui C, Collins T, Venkat K, Ayutyanont N, Vickery K, Kubomoto S. Adult Onset Still’s Disease: A Retrospective Study of Objective Manifestations and Outcomes [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/adult-onset-stills-disease-a-retrospective-study-of-objective-manifestations-and-outcomes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adult-onset-stills-disease-a-retrospective-study-of-objective-manifestations-and-outcomes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology